DataMeds says Helomics ChemoFx test gains Humana Medicaid coverage

DataMeds AI shares rose 14.14% premarket Monday to $3.37 after closing Friday at $2.96, down 12.94%. The swing followed the company's Oct. 12, 2026 announcement that subsidiary Helomics received a Humana Medicaid coverage determination for ChemoFx, effective July 22, 2026. Humana's Medicaid Coverage Policy Adoption Forum placed the test under its Coverage Determination for Pharmacogenomics Testing. Eligible members may qualify for ovarian, cervical, endometrial, fallopian tube, primary peritoneal cancers, or gynecologic sarcomas, billed under CPT codes 81535 and 81536, when facing rare cancers without established treatment guidelines, initial biopsy or surgery, recurrent or treatment-refractory disease, or inability to tolerate recommended treatment. Coverage does not apply to all Humana plans. Helomics operates a CLIA-certified lab in Pittsburgh. ChemoFx is a laboratory-developed test without FDA clearance or approval. A 2015 peer-reviewed study estimated mean recurrent ovarian cancer chemotherapy costs at $48,758 empirical, $33,187 assay-assisted, and $23,986 assay-adherent. DataMeds AI is Tampa-based (NASDAQ:MEDS). No factual disputes appear in the available record. Expected testing volumes and revenue impact were not disclosed.